GlycoMimetics Incorporated
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, GlycoMimetics Incorporated sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
GlycoMimetics Incorporated: 15 sponsored US clinical trials, none currently recruiting.
GlycoMimetics Incorporated sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 11 completed. 2 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage).
Top-decile sponsor footprint
GlycoMimetics Incorporated ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (73.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
NCT04197999
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
NCT03616470
A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.
NCT02998099
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
NCT02871570
Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers
NCT02931214
Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)
NCT02744833
A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects
NCT02813798
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
NCT02433158
A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects
NCT02703051
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
NCT02306291
Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects
NCT02271113
Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers
NCT02168595
A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects
NCT01941511
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
NCT01119833
Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease
NCT00911495
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 12 |
| Phase 2 | 1 |
| Phase 3 | 2 |
How the GlycoMimetics Incorporated early-phase archive is shaped
15 indexed studies, none listed as recruiting (0% open); 11 completed (73%).
Phase mix: 2 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Therapeutic area indexing for this sponsor is limited in the public registry.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
GlycoMimetics Incorporated: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
GlycoMimetics Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this GlycoMimetics Incorporated page
15 registered trials is a research-attention snapshot, not an endorsement of GlycoMimetics Incorporated or any single study.
- None of GlycoMimetics Incorporated's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. GlycoMimetics Incorporated pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.